Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in ...

First-line treatment with enfortumab vedotin and pembrolizumab provides durable benefits over chemotherapy in advanced urothelial carcinoma.

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, ...

Pfizer & Astellas’ Padcev plus Keytruda shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer: New York Wednesday, February 12, 20 ...

Dr Scott Tagawa discusses how dose adjustments can optimize the use of enfortumab vedotin in urothelial cancer.

Patients treated with enfortumab vedotin and pembrolizumab saw a 49% reduction in the risk of death and a 52% reduction in the risk of disease progression or death when compared to those receiving ...

enfortumab vedotin, and Merck's drug, pembrolizumab, has significantly improved survival rates for patients with advanced bladder cancer. The latest results from the trial, which focused on ...

which showed that the combination of enfortumab vedotin and pembrolizumab continues to provide superior efficacy compared to chemotherapy in the first-line treatment of patients with locally advanced ...